Conditions · Pancreatic cancer
Pancreatic cancer — Phase 2 trials
30 open options
- TRIALPHASE1 / PHASE2NOT_YET_RECRUITING
Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies
RP-001
- TRIALPHASE1 / PHASE2RECRUITING
Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
Biospecimen Collection · Computed Tomography · Core Biopsy — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors
VB15010 — 1 site
- TRIALPHASE2RECRUITING
EUS-RFA PANCARDINAL-1 Trial
Endoscopic Ultrasound (EUS)-Guided Radiofrequency Ablation (RFA) · Neoadjuvant Chemotherapy (NAC) — 1 site
- TRIALPHASE2RECRUITING
mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer Patients
Folfirinox — 1 site
- TRIALPHASE1 / PHASE2NOT_YET_RECRUITING
CD318-targeted CAR-T Cell Therapy in Patients With Pancreatic Cancer (ResCPa)
CD318-CAR-T cells
- TRIALPHASE1 / PHASE2RECRUITING
Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
Gemcitabine · Nab paclitaxel · Erlotinib — 1 site
- TRIALPHASE2 / PHASE3RECRUITING
Vitamin C Plus Cordyceps to Chemotherapy Related Anemia in Pancreatic Cancer
Vitmain C plus herbal medicine — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
Carbon Nanoparticle-Loaded Iron [CNSI-Fe] · Carbon Nanoparticle-Loaded Iron — 9 sites
- TRIALPHASE2RECRUITING
24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC
Nab-paclitaxel + Gemcitabine · modified FOLFIRINOX (mFOLFIRINOX) — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study
Low-dose Radiotherapy · Pucotenlimab · AG regimen — 1 site
- TRIALPHASE2NOT_YET_RECRUITING
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Pancreatic Cancer
HLX43 DOSE 1 (2.5 mg/kg) · HLX43 DOSE 2 (3.0 mg/kg)
- TRIALPHASE2RECRUITING
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
Riluzole · Placebo — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
Autologous dual-target CAR-T cells selected from the predefined target library. · Fludarabine · Cyclophosphamide — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
[68Ga]Ga-DPI-4452 · [177Lu]Lu-DPI-4452 — 10 sites
- TRIALPHASE1 / PHASE2RECRUITING
Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source
Directional Brachytherapy Source Implant — 6 sites
- TRIALPHASE2NOT_YET_RECRUITING
SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial
Biospecimen Collection · Computed Tomography · Electronic Health Record Review — 1 site
- TRIALPHASE1 / PHASE2NOT_YET_RECRUITING
Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations
JAB-23E73 tablet，nab-paclitaxel，gemcitabine — 13 sites
- TRIALPHASE1 / PHASE2RECRUITING
Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer
AGEN2373 · Balstilimab · Cyclophosphamide — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1) · EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1) · Lymphodepleting chemotherapy (Flu/Cy) — 1 site
- TRIALPHASE2RECRUITING
Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer
Adebrelimab · Oxaliplatin 100 MG · Irinotecan liposome — 1 site
- TRIALPHASE2 / PHASE3RECRUITING
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
Trastuzumab · Pertuzumab — 27 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
AMXI-5001:Dose Escalation Phase I · AMXI-5001:Dose Expansion Phase II — 4 sites
- TRIALPHASE2NOT_YET_RECRUITING
A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD
Surufatinib 250mg/d qd once daily — 1 site
- TRIALPHASE2NOT_YET_RECRUITING
AG Followed by FOLFIRINOX Both Combined With PD-L1 Antibodies as a Conversion Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer.
Treatment: AG & anti-PD-L1 + FOLFIRINOX & anti-PD-L1
- TRIALPHASE1 / PHASE2RECRUITING
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
LUM015 · LUM 2.6 Imaging Device — 1 site
- TRIALPHASE2RECRUITING
BEFAST Study, [68Ga]Ga-FAPI Total Body PET/CT for Better and Faster Imaging in Cancer
[68Ga]Ga-FAPI-46 — 1 site
- TRIALPHASE2NOT_YET_RECRUITING
Histamine Dihydrochloride and Interleukin-2 in Primary Resectable Pancreatic Cancer
Histamine Dihydrochloride (HDC) · Interleukin-2 (IL-2)
- TRIALPHASE2NOT_YET_RECRUITING
Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic Cancer
Irinotecan liposome (Nal-IRI) in combination with 5-FU/sodium levofolinate
- TRIALPHASE2RECRUITING
Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
Psilocybin therapy — 3 sites
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.